Blog

Long-term follow-up for patients with APL

www.aacr.org/patients-caregivers/cancer/acute-myeloid-leukemia/

Dec 4, 2024, 18:01

Long-term follow-up for patients with APL

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a paper by Wei Ying Jen et al. on X:

“Just in time for ASH24: Long-term Phase 2 follow-up for patients with APL treated with ATRA, ATO, and GO led by Dr. Wei Ying Jen and Dr. Ravandi at MD Anderson Cancer Center.”

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia

Authors: Wei-Ying Jen BM, BCh, Jennifer Marvin-Peek MD, Hagop M. Kantarjian MD, Yesid Alvarado MD, Gautam Borthakur MD, Elias Jabbour MD, William Wierda MD, Tapan M. Kadia MD, Naval G. Daver MD, Courtney D. DiNardo MD, Nicholas J. Short MD, Nitin Jain MD, Alessandra Ferrajoli MD, Steven Kornblau MD, Musa Yilmaz MD, Maro Ohanian MD, David McCue BSc, Jan Burger MD, Danielle Hammond MD, Keyur Patel MD, Ghayas C. Issa MD, Naveen Pemmaraju MD, Koji Sasaki MD, Abhishek Maiti MD, Hussein A. Abbas MD, Kelly Chien MD, Koichi Takahashi MD, Fadi Haddad MD, Prithviraj Bose MD, Lucia Masarova MD, Guillermo Montalban-Bravo MD, Mahesh Swaminathan MD, Mark Brandt BS, Sherry Pierce BA, BSN, Guillermo Garcia-Manero MD, Farhad Ravandi MD

Naveen Pemmaraju is a Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center (MDACC) and Executive Director of MDACC Network. He is also the Leukemia Hematology/Oncology Course Director.

His research work has been focused on improving outcomes and developing novel therapies for patients with rare, and ultra-rare, myeloid malignancies; including adolescents, young adults, and older adult patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), MPN and AML.

More posts featuring Naveen Pemmaraju.